Pulmobreathe tablets covered with a blister pack of 20 pcs

Pulmobreathe is a combined drug that is used for inflammatory diseases of the respiratory tract. The activity of the drug is determined by two active substances – acetylcysteine ​​and ambroxol.

Acetylcysteine ​​is a mucolytic, expectorant and antioxidant agent. The uniqueness of the molecule lies in its direct effect on the structure of sputum. Acetylcysteine ​​reduces viscosity, improves excretion and increases the amount of sputum produced of any type – mucous, purulent, muco-purulent. By suppressing the formation of free radicals, a weak anti-inflammatory effect is realized. Pulmobreathe contains 200 mg of acetylcysteine.

Ambroxol is the prescribed mucolytic agent, both as a monotherapy and as part of a combined treatment or drug. The substance has a pronounced expectorant effect, which is provided due to the normalization of sputum components. Ambroxol stimulates synthesis and production of pulmonary surfactant, necessary for protection and assimilation of oxygen. It is also worth noting the anti-inflammatory, local immunomodulatory, bronchodilating effects. Ambroxol accelerates the penetration of antibiotics into the lung tissue. As a component of Pulmobreathe, ambroxol is contained in a dose of 30 mg.

The combination of active substances in Pulmobreathe is expedient and effective. Acetylcysteine ​​and ambroxol potentiate the therapeutic effect of each other, therefore the speed of recovery increases and the risk of developing complications of the disease decreases.

The dose of the active substances of the medicinal product is intended for adults and children over 12 years of age. A daily dose of ambroxol and acetylcysteine, which are part of Pulmobreathe, is provided if taken three times a day.

When using, it is necessary to refer to the manifestation of adverse reactions and inform the doctor about them. Usually, the drug is well tolerated if the recommended doses are followed.

Pulmobreathe significantly eases the course of the disease, accelerates the recovery of bronchopulmonary functions, has a high safety profile and good tolerability.